Physician profile
Kerwin K Cumberbatch
NPI 1669785788
$1,560.17
in general payments reported to CMS, 2019-2025
32 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $327 · 2021: $25.21 · 2022: $15.99 · 2023: $51.03 · 2024: $14.45 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186 · Education: $72.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.94 |
| Education | $72.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $193.61 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $157.48 | 2019-2022 | |
| Janssen Biotech, INC. | $138.21 | 2019-2025 | Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $110.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $84.27 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $79.73 | 2019-2020 | |
| Pfizer INC. | $65.41 | 2019-2020 | |
| Celgene Corporation | $62.70 | 2019 | |
| Amgen INC. | $51.38 | 2019-2023 | |
| Gilead Sciences, INC. | $49.32 | 2019-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $45.96 | 2020 | |
| Astellas Pharma US INC | $45.77 | 2019-2025 | Vyloy |
| Array Biopharma INC | $45.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.87 | 2019 | |
| Pharmacosmos Therapeutics INC. | $36.53 | 2025 | Monoferric |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $31.31 | 2019 | |
| Glaxosmithkline, LLC. | $31.28 | 2025 | Jemperli |
| Seagen INC. | $28.77 | 2020-2021 | |
| Taiho Oncology, INC. | $24.83 | 2025 | |
| Genzyme Corporation | $23.88 | 2020 | |
| Eisai INC. | $23.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.28 | 2019 | |
| Adaptive Biotechnologies Corporation | $21.70 | 2023 | Clonoseq |
| Clovis Oncology, INC. | $21.45 | 2019 | |
| Kite Pharma, INC. | $19.02 | 2020 | |
| Heron Therapeutics, INC. | $18.98 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.37 | 2020 | |
| Emd Serono, INC. | $16.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.15 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.13 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $12.43 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerwin Cumberbatch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.